Patent US3079279A successfully refreshed from Google Patents.
US4141972A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Purine nucleoside 5'-phosphate (mono, di or tri) 3'(2')-diphosphates and processes for their preparation
Assignee: Sanraku Ocean Co Ltd
•
Filing: 1977-04-27
•
Granted: 1979-02-27
•
Expires: 1997-04-27
Abstract
Abstract New purine nucleoside 5'-phosphate (mono, di or tri) 3'(2')-diphosphates and the sodium, lithium and potassium salts thereof are elaborated by the enzymatic transfer of pyrophosphoryl group from ATP (adenosine triphosphate), dATP (deoxyadenosine triphosphate) and pppApp (adenosine 5'-triphosphate 3'(2') diphosphate) to specified 5'-purine nucleotides, and a new nucloetide pyrophosphotransferase used for this enzyme reaction is produced by actinomycetes and other microorganisms and recovered from the culture filtrate and mycelium by the conventional methods for recovering enzymes. These compounds are useful for treating leukemia L1210 in mice.
Inventors
- 👤 Toyokazu Nishino
- 👤 Yasutaro Hamagishi
- 👤 Toshikazu Oki
- 👤 Sawao Murao
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 16:50
CPC Classifications
C; C07; C07H; C07H21/00; C07H21/02; A; A61; A61K; A61K38/00; A61K38/16; A61K38/43; A61K38/45; C07H19/00; C07H19/02; C07H19/04; C07H19/16; C07H19/20; C12; C12N; C12N9/00; C12N9/10; C12N9/12; C12P; C12P19/00; C12P19/26; C12P19/28; C12P19/30; C12P19/32; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/822; Y10S435/886; Y10S435/908
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
73 words
A purine nucleoside 5'-(mono, di or tri) phosphate 3'(2')-diphosphate and the corresponding purine nucleoside 5'-(di or tri) phosphate 3'(2')-monophosphate and the salts thereof selected from the group consisting of adenosine-5'-monophosphate 3'(2')-diphosphate(pApp), adenosine-5'-diphosphate 3'(2')-diphosphate(ppApp), adenosine-5'-triphosphate 3'(2')-diphosphate(pppApp), guanosine-5'-monophosphate 3'(2')-diphosphate(pGpp), inosine-5'-monophosphate 3'(2')-diphosphate(pIpp), inosine-5'-diphosphate 3'(2')-diphosphate(ppIpp), inosine-5'-triphosphate 3'(2')-diphosphate(pppIpp), β,γ-methylene adenosine 5'-triphosphate 3'(2')-diphosphate(p(CH 2 )ppApp), guanosine-5'-triphosphate 3'(2')-monophosphate(pppGp), inosine-5'-diphosphate 3'(2')-monophosphate(ppIp), inosine-5'-triphosphate 3'(2')-monophosphate(pppIp), β,γ-methylene adenosine-5'-triphosphate 3'(2')-monophosphate(p(CH 2 )ppAp) and β,γ-methylene guanosine-5'-triphosphate 3'(2')-monophosphate(p(CH 2 )ppGp) and lithium, potassium and sodium salts thereof.
Claim 2
Dependent Claim
73 words
A purine nucleoside 5'-(mono, di or tri) phosphate 3'(2')-diphosphate and the corresponding purine nucleoside 5'-(di or tri) phosphate 3'(2')-monophosphate and the salts thereof selected from the group consisting of adenosine-5'-monophosphate 3'(2')-diphosphate(pApp), adenosine-5'-diphosphate 3'(2')-diphosphate(ppApp), adenosine-5'-triphosphate 3'(2')-diphosphate(pppApp), guanosine-5'-monophosphate 3'(2')-diphosphate(pGpp), inosine-5'-monophosphate 3'(2')-diphosphate(pIpp), inosine-5'-diphosphate 3'(2')-diphosphate(ppIpp), inosine-5'-triphosphate 3'(2')-diphosphate(pppIpp), β,γ-methylene adenosine 5'-triphosphate 3'(2')-diphosphate(p(CH 2 )ppApp), guanosine-5'-triphosphate 3'(2')-monophosphate(pppGp), inosine-5'-diphosphate 3'(2')-monophosphate(ppIp), inosine-5'-triphosphate 3'(2')-monophosphate(pppIp), β,γ-methylene adenosine-5'-triphosphate 3'(2')-monophosphate(p(CH 2 )ppAp) and β,γ-methylene guanosine-5'-triphosphate 3'(2')-monophosphate(p(CH 2 )ppGp) and lithium, potassium and sodium salts thereof.
Claim 3
Dependent Claim
42 words
A pharmaceutical composition for intraperitoneal administration to animals comprising a substance according to claim 1 in a concentration sufficient to suppress an accumulation of abdominal dropsy without causing toxicity to the recipient in vivo in combination with a pharmaceutically acceptable nontoxic carrier.
Claim 4
Dependent Claim
42 words
A method for chemotherapeutically treating an animal bearing ascites tumor including an accumulation of abdominal dropsy, which comprises administering a compound according to claim 1 to said animal in a dosage sufficient to lower said accumulation without causing toxicity to said animal.
Claim 5
Dependent Claim
11 words
A pharmaceutical composition of claim 2 wherein said animals are rodents.
Claim 6
Dependent Claim
11 words
A method of claim 3 wherein said animal is a rodent.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-02-26 | 1982-08-28 | 1983-02-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-02-26 | 1986-08-28 | 1987-02-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-02-26 | 1990-08-28 | 1991-02-27 | $7700.00 | Window Closed / Lapsed |